Dry eye syndrome is a clinical condition wherein the patient experiences ocular and conjunctival irritation due to decreased tear production and/or excessive tear evaporation.
It is associated with increased osmolarity of the tear film and inflammation of the ocular surface.
Goal of treatments are to relieve symptoms of patients, to improve visual acuity & quality of life of patients, to restore ocular surface & tear film to normal homeostatic state and to correct the underlying defect.
Fiscella RG. Understanding dry eye disease: a managed care perspective. Am J Manag Care. 2011 Dec;17(Suppl 16):S432-A439. Accessed 23 Jan 2012. PMID: 22435675
Jackson WB. Management of dysfunctional tear syndrome: a Canadian consensus. Can J Ophthamol. 2009 Aug;44(4):385-394. doi: 10.3129/i09-015. Accessed 23 Jan 2012. PMID: 19606158
International Dry Eye Committee. 2007 report of the International Dry Eye Workshop (DEWS). Ocul Surf. 2007 Apr;5(2):75-92. Accessed 23 Jan 2012. PMID: 17508116
Perry HD. Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care. 2008 Apr;14(3 Suppl):S79-S87. PMID: 18452371
American Academy of Ophthalmology Cornea/External Disease Panel. Preferred practice pattern guidelines. Dry eye syndrome. San Francisco, CA: American Academy of Ophthalmology. http://one.aao.org/. 2013. Accessed 23 Jan 2012.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.